Medical Marketing and Media - FDA to Lilly: Can Cymbalta journal ads
Saturday, November 15th, 2008THE FDA called on Eli Lilly to stop journal ads for Cymbalta as a treatment for nerve pain caused by diabetes because the ads fail to address drug risks.
In a Sept. 9 untitled letter posted by the agency last month, the Divi…
